The majority of our work involves studies that support the development of new ocular therapies and devices. We have also participated in investigative studies that have advanced the field of preclinical development. You may also filter for Development phase, (e.g., Safety) ophthalmology discipline (e.g., ocular imaging) and therapeutic class (e.g., Gene and Cell therapies).
Publication Reference Index
Filter Results by...
Publication Title | Investigation Type | Development Phase | Therapy Class | Discipline(s) | |||
---|---|---|---|---|---|---|---|
VEP and PERG acuity in anesthetized young adult rhesus monkeys | Advancing the Field | Safety |
|
Detail | VEP and PERG acuity in anesthetized young adult rhesus monkeysVisual neuroscience, 16(4), pp.607-617. |
||
Swelling and loss of photoreceptors in chronic human and experimental glaucomas | Advancing the Field | Pharmacology |
|
Detail | Swelling and loss of photoreceptors in chronic human and experimental glaucomasArchives of ophthalmology, 118(2), pp.235-245. |
||
Lucentis Safety Evaluation of Intravitreal Administration of rhuFab VEGF in Cynomolgus Monkeys for 3 Months |
Approved Therapy | Safety | Fab Protein |
|
Detail | Lucentis
|
|
Determination of the neuroprotective effects of hsp-27 and PC3-96 against ischemic insult. | Advancing the Field | Investigative | Heat Shock Protein 27 |
|
Detail | Determination of the neuroprotective effects of hsp-27 and PC3-96 against ischemic insult.35th MUSC Student Research Day, Abstr 74. November 3, 2000. |
|
Lucentis Safety Evaluation of Differing Schedules of Intravitreal Administration of rhuFab VEGF in Cynomolgus Monkeys for 2 Months |
Approved Therapy | Safety | Fab Protein |
|
Detail | Lucentis
|
|
Lucentis Characterization of a Monkey Model of Laser-Induced Choroidal Neovascularization (CNV) |
Approved Therapy | Safety | Fab Protein |
|
Detail | Lucentis
|
|
Lucentis 26-Week Intravitreal Injection Toxicity Study with rhuFab VEGF in Cynomolgus Monkeys with an 8-Week Recovery |
Approved Therapy | Safety | Fab Protein |
|
Detail | Lucentis
|
|
Evaluation of intra-and interobserver reliability and image reproducibility to assess usefulness of high-resolution ultrasonography for measurement of anterior segment structures of canine eyes | Advancing the Field | Investigative |
|
Detail | Evaluation of intra-and interobserver reliability and image reproducibility to assess usefulness of high-resolution ultrasonography for measurement of anterior segment structures of canine eyesAmerican journal of veterinary research, 66(10), pp.1775-1779. |
||
Eylea Pharmacokinetics and ocular tissue penetration of VEGF Trap after intravitreal injections in rabbits |
Approved Therapy | Pharmacokinetics | Fusion Protein |
|
Detail | Eylea
|
|
Multifocal visual evoked potentials in the anesthetized non-human primate | Advancing the Field | Safety |
|
Detail | Multifocal visual evoked potentials in the anesthetized non-human primateCurrent eye research, 31(10), pp.885-893. |
||
Measurement of regional choroidal blood flow in rabbits and monkeys using fluorescent microspheres | Advancing the Field | Investigative |
|
Detail | Measurement of regional choroidal blood flow in rabbits and monkeys using fluorescent microspheresArchives of Ophthalmology, 124(6), pp.860-868. |
||
Eylea Safety evaluation of intravitreal administration of VEGF trap in cynomolgus monkeys for 13 weeks. |
Approved Therapy | Safety | Fusion Protein |
|
Detail | Eylea
|
|
Bimatoprost, prostamide activity, and conventional drainage | Therapy Development | Investigative | Prostaglandin |
|
Detail | Bimatoprost, prostamide activity, and conventional drainageInvestigative ophthalmology & visual science, 48(9), pp.4107-4115 |
|
Evaluation of EIAV Based Lentiviral Vectors Following Ocular Delivery in the Nonhuman Primate Model: Development of RetinoStat® | Therapy Development | Safety | Gene and Cell |
|
Detail | Evaluation of EIAV Based Lentiviral Vectors Following Ocular Delivery in the Nonhuman Primate Model: Development of RetinoStat®Investigative Ophthalmology & Visual Science, 49(13), pp.5340-5340 |
|
Pachymetry in New Zealand White Rabbits, Beagle Dogs, and Cynomolgus Monkeys. | Advancing the Field | Safety |
|
Detail | Pachymetry in New Zealand White Rabbits, Beagle Dogs, and Cynomolgus Monkeys.Investigative Ophthalmology & Visual Science, 49(13), pp.645-645 |
||
Corneal endothelial cell density measurements using noncontact specular microscopy in rabbits, dogs and monkeys | Advancing the Field | Safety |
|
Detail | Corneal endothelial cell density measurements using noncontact specular microscopy in rabbits, dogs and monkeysInvestigative Ophthalmology & Visual Science, 49(13), pp.2819-2819 |
||
Standardized Full-Field Electroretinography in Cynomolgus Monkeys | Advancing the Field | Safety |
|
Detail | Standardized Full-Field Electroretinography in Cynomolgus MonkeysInvestigative Ophthalmology & Visual Science, 49(13), pp.5816-5816 |
||
Ocular and systemic safety evaluation of calcium formate as a dietary supplement | Therapy Development | Clinical Trial | Small Molecue |
|
Detail | Ocular and systemic safety evaluation of calcium formate as a dietary supplementJournal of ocular pharmacology and therapeutics, 25(3), pp.223-230 |
|
Retinal effects of 6 months of daily use of tadalafil or sildenafil | Therapy Development | Clinical Trial | Small Molecue |
|
Detail | Retinal effects of 6 months of daily use of tadalafil or sildenafilArchives of ophthalmology, 127(4), pp.367-373 |
|
Bilateral optic atrophy: a background finding in cynomolgus macaques used in toxicologic research | Advancing the Field | Safety |
|
Detail | Bilateral optic atrophy: a background finding in cynomolgus macaques used in toxicologic researchInvestigative Ophthalmology & Visual Science, 50(13), pp.5344-5344 |
||
Continuous Monitoring of Intraocular Pressure in New Zealand White Rabbits Using Telemetry | Advancing the Field | Pharmacology |
|
Detail | Continuous Monitoring of Intraocular Pressure in New Zealand White Rabbits Using TelemetryToxicologist Supplement (2009) |
||
Ocular inflammation in cynomolgus macaques following intravenous administration of a human monoclonal antibody | Therapy Development | Safety | Monoclonal Antibodies |
|
Detail | Ocular inflammation in cynomolgus macaques following intravenous administration of a human monoclonal antibodyInternational journal of toxicology, 28(1), pp.5-16 |
|
Lucentis Prevention of Laser Photocoagulation Induced Choroidal Neovascularization Lesions by Intravitreal Doses of Ranibizumab in Cynomolgus Monkeys |
Approved Therapy | Pharmacology | Fab Protein |
|
Detail | Lucentis
|
|
Serial multifocal electroretinograms during long-term elevation and reduction of intraocular pressure in non-human primates | Advancing the Field | Safety |
|
Detail | Serial multifocal electroretinograms during long-term elevation and reduction of intraocular pressure in non-human primatesDoc Ophthalmol. 2010 Jun;120(3):273-89. doi: 10.1007/s10633-010-9231-4. Epub 2010 Apr 27. ABSTRACT The purpose of this study was to evaluate the relationship between elevations of intraocular pressure (IOP) and the multifocal electroretinogram (mfERG) in non-human primates. Experimental glaucoma was induced in 4 rhesus and 4 cynomolgus monkeys by laser trabecular meshwork destruction (LTD) in one eye. To evaluate the contribution of ganglion cells to mfERG changes, one monkey of each species had previously underwent unilateral optic nerve transection (ONT). After >or=44 weeks of elevation, the IOP was reduced by trabeculectomy in 2 non-transected animals. In the intact (non-transected) animals, there was an increase in the amplitude of the early mfERG waveforms (N1 and P1) of the first-order kernel (K1) throughout the period of IOP elevation in all of the rhesus, but not all of the cynomolgus monkeys. A species difference was also present as a decrease of the second-order kernel, first slice (K2.1) in all of the cynomolgus monkeys but only in 1 of the rhesus monkeys (the 1 with the ONT). Similar IOP effects on the mfERG were seen in the ONT animals. Surgical lowering of IOP resulted in a return of the elevated K1 amplitudes to baseline levels. However, the depressed K2.1 RMS in the cynomolgus monkeys did not recover. These results demonstrate species-specific changes in cone-driven retinal function during periods of elevated IOP. These IOP-related effects can occur in the absence of retinal ganglion cells and may be reversible. PMID:20422254 | PMC:PMC2933837 | DOI:10.1007/s10633-010-9231-4 |
||
Xiidra Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) |
Approved Therapy | Pharmacology | Protein | Detail | Xiidra
|
||
Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105 | Advancing the Field | Pharmacology |
|
Detail | Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4738-45. doi: 10.1167/iovs.09-4890. Epub 2010 Apr 14. ABSTRACT PURPOSE: To compare the relative contribution of VEGF and TNF-alpha in the development of laser-induced choroidal neovascularization (CNV) in monkeys and to exploit the feasibility of topical use of suitable antibody fragments for the prevention of experimental CNV. METHODS: To induce experimental CNV, small high-energy laser spots were used to treat several areas of the macula in the retinas of cynomolgus monkeys according to previously published protocols. To prevent abnormalities, bevacizumab (a potent VEGF inhibitor) and adalimumab or ESBA105 (potent TNF-alpha inhibitors) were given by intravitreal injection 1 week before and 1 week and 3 weeks after laser treatment. ESBA105 was also applied topically in a separate group. Control animals were treated with either intravitreal or topical saline. Eyes were monitored by ophthalmic examination, color photography, and fluorescein angiography. RESULTS: Inhibition of VEGF by bevacizumab completely blocked the formation of CNV. Both TNF-alpha inhibitors also significantly reduced laser-induced CNV abnormalities after intravitreal administration. Most important, topical use of the anti-TNF-alpha single-chain antibody fragment ESBA105 also reduced the formation of CNV. CONCLUSIONS: TNF-alpha contributes to laser-induced CNV formation, and its inhibition can be a new therapeutic target for CNV. This study suggests TNF-alpha as another therapeutic target for the prevention and treatment of CNV and adds to the emerging clinical data suggesting the therapeutic value of TNF-alpha inhibitors in age-related macular degeneration (AMD). Further, this study shows that topical therapy with suitable antibody fragments has the potential of being introduced to retinal disease treatment regimens. PMID:20393113 | DOI:10.1167/iovs.09-4890 |
||
Supplemental Clock-Hour Fluorescein Angiography (FA) Scoring and Image Analysis of Laser-Induced Choroidal Neovascularization (CNV) Lesions in Cynomolgus Monkeys | Advancing the Field | Pharmacology |
|
Detail | Supplemental Clock-Hour Fluorescein Angiography (FA) Scoring and Image Analysis of Laser-Induced Choroidal Neovascularization (CNV) Lesions in Cynomolgus MonkeysInvestigative Ophthalmology & Visual Science, 51(13), pp.6155-6155 |
||
INO-8875, an adenosine A1 agonist, lowers intraocular pressure through the conventional outflow pathway | Therapy Development | Investigative | Small Molecue, Adensine Receptor Agonist |
|
Detail | INO-8875, an adenosine A1 agonist, lowers intraocular pressure through the conventional outflow pathwayInvestigative Ophthalmology & Visual Science, 51(13), pp.3238-3238 |
|
Spectral domain OCT segmentation accuracy in monkeys | Advancing the Field | Safety |
|
Detail | Spectral domain OCT segmentation accuracy in monkeysInvestigative Ophthalmology & Visual Science, 51(13), pp.4401-4401 |
||
Gender differences in iridocorneal angle morphology: a potential explanation for the female predisposition to primary angle closure glaucoma in dogs | Advancing the Field | Investigative |
|
Detail | Gender differences in iridocorneal angle morphology: a potential explanation for the female predisposition to primary angle closure glaucoma in dogsVet Ophthalmol. 2012 Mar;15 Suppl 1:60-3. doi: 10.1111/j.1463-5224.2011.00956.x. Epub 2011 Oct 17. ABSTRACT OBJECTIVE: Female dogs have approximately twice the risk of males for developing primary angle closure glaucoma (PACG). The cause of this gender difference is unknown, but one theory proposes that the gender differences in iridocorneal angle morphology are involved in this risk differential. PROCEDURES: Fifty beagles (25 males, 25 females) were included into this study and had normal baseline ophthalmic examinations. Normal dogs were selected so as to avoid any potentially confounding influence of goniodysgenesis. Standardized 20-MHz high-resolution ultrasound images of the iridocorneal angle were acquired from one eye of each dog with the scan plane perpendicular to the limbus in the superior temporal quadrant. Images were imported into ImageJ, and the angle opening distance (AOD) and angle recess area (ARA) were measured by a masked observer, and the analysis of variance method was used to compare differences. RESULTS: The mean (±SD) AOD was significantly smaller for female dogs (0.847 ± 0.241 mm) vs. male dogs (1.058 ± 0.322 mm) P-value = 0.012. The mean (± SD) ARA tended to be smaller for female dogs (0.584 ± 0.278 mm) vs. male dogs (0.748 ± 0.385 mm), but this difference was not significant (P-value = 0.092). CONCLUSIONS: Female dogs have a significantly smaller AOD vs. males. This difference may render the female iridocorneal angle more susceptible to closure and may partially explain the 2:1 female/male predisposition to PACG. Further studies using goniodysgenic dogs are warranted. PMID:22050644 | DOI:10.1111/j.1463-5224.2011.00956.x |